These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain. Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Cupri A; Consoli C; Messina L; TirrĂ² E; Messina A; Di Raimondo F Leuk Res; 2009 Sep; 33(9):e157-8. PubMed ID: 19406471 [No Abstract] [Full Text] [Related]
11. STI571 (imatinib mesylate): the tale of a targeted therapy. Thambi P; Sausville EA Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302 [TBL] [Abstract][Full Text] [Related]
12. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib. Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152 [No Abstract] [Full Text] [Related]
18. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. Druker BJ J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403 [No Abstract] [Full Text] [Related]
19. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Sawyers CL Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882 [TBL] [Abstract][Full Text] [Related]
20. Towards a cure for chronic myeloid leukemia: are we there yet? Cortes J Semin Hematol; 2010 Oct; 47(4):299-301. PubMed ID: 20875545 [No Abstract] [Full Text] [Related] [Next] [New Search]